Daily Sepsis Research Analysis
Analyzed 39 papers and selected 3 impactful papers.
Summary
Today's most impactful sepsis research spans mechanistic discovery, immune-informed risk prediction, and rapid pathogen diagnosis. A Science Advances study identified a therapeutically tractable TG2–vimentin proteostasis axis driving macrophage inflammation and sepsis-associated liver injury, while a multicenter prospective study substantially improved prediction of sepsis-associated acute kidney injury by integrating immune biomarkers with clinical variables. A prospective evaluation of direct-from-blood molecular testing also demonstrated markedly higher pathogen detection than blood culture, particularly after prior antibiotic exposure.
Research Themes
- Mechanism-based therapeutic targets in sepsis
- Immune-informed prediction of sepsis-associated organ injury
- Rapid molecular diagnosis and antimicrobial stewardship
Selected Articles
1. Transglutaminase 2 regulates vimentin-dependent proteostasis during macrophage activation.
This mechanistic study identifies TG2 as a driver of sepsis-associated liver inflammation and multiorgan injury. TG2 cross-links vimentin in macrophages, altering proteostasis and sustaining NF-κB-related inflammatory signaling; genetic deletion or pharmacological inhibition of TG2 improved outcomes in septic mice.
Impact: The study links cytoskeletal remodeling, proteostasis, and innate immune activation through a previously unrecognized TG2–vimentin axis. The therapeutic benefit of TG2 inhibition in vivo provides a concrete mechanism-based strategy beyond nonspecific anti-inflammatory treatment.
Clinical Implications: TG2 inhibition could become a candidate treatment for sepsis-associated liver dysfunction and systemic inflammation, but clinical translation requires validation of target engagement, safety, and therapeutic timing in human sepsis.
Key Findings
- TG2 activity was increased in macrophages and promoted liver inflammation in septic mice.
- TG2 cross-linked vimentin, promoting oligomerization, intermediate filament remodeling, and inflammatory macrophage activation.
- Genetic or pharmacological inhibition of TG2 improved survival and reduced multiorgan inflammation.
- Vimentin deficiency enhanced proteasome recruitment and degradation of proinflammatory mediators such as Traf6.
Methodological Strengths
- Integrated in vivo mouse experiments, macrophage loss-of-function and gain-of-function studies, and proteomic profiling.
- Established a mechanistic link between TG2 activity, vimentin modification, proteostasis, and inflammatory signaling.
Limitations
- The principal efficacy evidence was generated in mouse and cellular models, whose translation to human sepsis remains uncertain.
- The supplied abstract does not provide the clinical sample size or detailed pharmacokinetic and toxicity information for TG2 inhibition.
Future Directions: Future work should validate the TG2–vimentin axis in human sepsis, define the optimal therapeutic window, develop selective TG2 inhibitors, and test efficacy alongside standard antimicrobial and organ-support therapies.
Sepsis-associated liver dysfunction is a life-threatening condition with a high mortality rate and no mechanism-based therapy. In this study, we identify the cross-linking enzyme transglutaminase 2 (TG2) as a driver of liver inflammation by activating macrophages in a mouse model of sepsis. Pharmacological inhibition of TG2 improves survival and reduces multiorgan inflammation, with the liver as a primary therapeutic target. Mechanistically, TG2 activity was up-regulated in macrophages, where it cross-linked vimentin to promote oligomerization and intermediate filament remodeling. Genetic ablation of TG2 or vimentin suppressed macrophage cytokine production and attenuated lipopolysaccharide-induced inflammation.
2. Unveiling the immuno-inflammatory endotype of sepsis-associated acute kidney injury: a machine learning-based approach.
In a multicenter prospective cohort of 1,551 patients with sepsis, new-onset sepsis-associated acute kidney injury occurred in 44.8% and was associated with increased mortality. An XGBoost model integrating immune, complement, T-cell, and routine clinical variables achieved an AUC of 0.914, outperforming a clinical-only model with an AUC of 0.788.
Impact: The study moves risk prediction beyond delayed functional kidney markers by defining an immuno-inflammatory endotype associated with high risk. Its large prospective multicenter design and decision-curve analysis support potential clinical utility, although external validation is still needed.
Clinical Implications: The integrated model may enable earlier identification of patients at high risk for sepsis-associated acute kidney injury and support intensified monitoring, nephrotoxin avoidance, hemodynamic optimization, and enrollment into prevention trials.
Key Findings
- New-onset sepsis-associated acute kidney injury occurred in 44.8% of 1,551 septic patients and was associated with increased mortality.
- The high-risk endotype included elevated immunoglobulin A and procalcitonin, depleted complement component 3, reduced naïve CD4+ T cells, and expanded CD28+CD4+ T cells.
- The clinical-immune XGBoost model achieved an AUC of 0.914 versus 0.788 for the clinical model.
- Decision-curve analysis demonstrated greater net clinical benefit for the integrated model.
Methodological Strengths
- Large multicenter prospective cohort involving 1,551 patients across five tertiary hospitals.
- Integrated multidimensional immune biomarkers with established clinical severity variables and assessed decision-curve benefit.
Limitations
- The model was developed in hospitals in Beijing, so generalizability to other populations and healthcare systems requires external validation.
- Machine-learning discrimination does not establish that biomarker-guided intervention improves kidney outcomes or survival.
Future Directions: Future studies should perform temporal and geographic external validation, simplify the biomarker panel for bedside use, assess calibration across subgroups, and conduct prospective impact trials testing biomarker-guided kidney-protective interventions.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a frequent and high-mortality complication in critically ill patients. Current diagnostic criteria rely on functional markers that often lag behind the onset of renal injury. While immune dysregulation is central to SA-AKI pathogenesis, few prediction models systematically integrate multidimensional immune phenotypes. METHODS: The present analysis was based on a multicenter prospective cohort study involving 1,551 septic patients. The study was carried out across five tertiary hospitals in Beijing. Clinical data and immuno-inflammatory biomarkers (including humoral, complement, and T lymphocyte subsets) were collected within 24 hours of sepsis diagnosis. An Extreme Gradient Boosting (XGBoost) model was then developed to predict SA-AKI.
3. Evaluation of a Direct-from-Blood Molecular Diagnostic Platform for Pathogen Detection in Critically Ill Patients: A Prospective Observational Cohort Study.
This prospective observational cohort evaluated a direct-from-blood multiplex PCR platform detecting 19 bacterial and fungal species in 165 critically ill patients. The assay detected bloodstream infection in 15.2% of samples compared with 4.3% for blood culture and identified pathogens in all 20 patients who had received antibiotics during the preceding 48 hours, whereas blood culture was positive in only four.
Impact: The platform addresses a major diagnostic weakness in sepsis: low blood-culture yield after antibiotics. Faster and more sensitive pathogen identification could support earlier targeted therapy and reduce unnecessary broad-spectrum antimicrobial exposure.
Clinical Implications: Direct-from-blood molecular testing may complement or, in selected situations, provide information unavailable from blood culture, particularly after antibiotic exposure. Clinical implementation should remain linked to antimicrobial stewardship, organism coverage, resistance testing, and confirmation of clinical significance.
Key Findings
- The RaPID/BSI platform detected 19 bacterial and fungal species directly from whole blood.
- Pathogen detection yield was 15.2% with RaPID/BSI versus 4.3% with blood culture.
- Among 20 patients who had received antibiotics within 48 hours before blood collection, RaPID/BSI detected pathogens in all 20, whereas blood culture was positive in only four.
- Of 27 RaPID/BSI-positive patients, 25 had clinically defined infections and 18 had corroborating microbiological data.
Methodological Strengths
- Prospective evaluation in critically ill patients undergoing routine blood-culture testing.
- Included assessment of diagnostic performance in the clinically important setting of recent antibiotic exposure and used corroborating clinical and microbiological data.
Limitations
- The cohort included only 165 samples and was not a randomized comparison of molecular testing-guided versus standard antibiotic management.
- The assay detects a limited panel of 19 organisms and does not by itself establish antimicrobial susceptibility or prove that a detected organism is the cause of sepsis.
Future Directions: Future trials should evaluate patient-centered outcomes, time to effective therapy, antibiotic days of therapy, resistance detection, cost-effectiveness, and performance across broader pathogen panels and diverse healthcare settings.
RATIONALE: Defining the microbial etiology of sepsis is difficult but has important implications for antibiotic stewardship and prognosis. We explore the diagnostic yield of a novel, direct-from-blood multiplex polymerase chain reaction in intensive care unit patients with suspected sepsis. METHODS: From March 2022 to March 2024, patients were included if the clinical team ordered a blood culture. In study participants, an additional 6 mL of whole blood was collected by the phlebotomist. Samples were analyzed by the RaPID/BSI platform, a polymerase chain reaction-based assay that detects 19 bacterial and fungal species direct from whole blood. RESULTS: A total of 165 samples were included in the final cohort. Of these, 27 patients had a positive RaPID/BSI result and 8 patients had positive blood cultures with 1 pathogen not included in the RaPID/BSI panel.